Trial Profile
A randomized, double-Blind, parallel-group, placebo-controlled study in patients with symptomatic overactive bladder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 01 Jan 2022 Results of post-hoc analysis using pooled data from phase IIb and a phase III studies (NCT00527033 & NCT00966004) assessing efficacy of mirabegron were published in the International Journal of Urology.
- 10 Mar 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 10 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.